Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.

Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2017 Aug;58(8):1849-1858. doi: 10.1080/10428194.2016.1271946. Epub 2017 Jan 13.

PMID:
28084849
2.

A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.

Lefrère F, Mauge L, Réa D, Ribeil JA, Dal Cortivo L, Brignier AC, Aoun C, Larghéro J, Cavazzana-Calvo M, Micléa JM.

Transfusion. 2013 Mar;53(3):564-9. doi: 10.1111/j.1537-2995.2012.03744.x. Epub 2012 Jun 21.

PMID:
22725259
3.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1564-72. doi: 10.1016/j.bbmt.2012.05.017. Epub 2012 Jun 6.

4.

Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.

Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.

Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.

PMID:
27859332
5.

Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.

Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.

Transfusion. 2011 Oct;51(10):2175-82. doi: 10.1111/j.1537-2995.2011.03136.x. Epub 2011 Apr 14.

PMID:
21492180
6.
7.

Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.

Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S.

Biol Blood Marrow Transplant. 2013 Jan;19(1):87-93. doi: 10.1016/j.bbmt.2012.08.010. Epub 2012 Aug 23.

8.

Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience.

Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E.

Leuk Res. 2011 Jun;35(6):712-4. doi: 10.1016/j.leukres.2010.12.036. Epub 2011 Jan 26.

PMID:
21276613
9.

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.

Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, Mir FA, Shao J, McFarland K, Trinkaus K, Shannon W, Deych E, Yu J, Vij R, Stockerl-Goldstein K, Cashen AF, Uy GL, Abboud CN, Westervelt P, DiPersio JF.

Blood. 2017 May 11;129(19):2680-2692. doi: 10.1182/blood-2016-09-739722. Epub 2017 Mar 14.

10.

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.

Stover JT, Shaw JR, Kuchibhatla M, Horwitz ME, Engemann AM.

Biol Blood Marrow Transplant. 2017 Aug;23(8):1290-1294. doi: 10.1016/j.bbmt.2017.04.007. Epub 2017 Apr 11.

11.

Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.

Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.

Acta Haematol. 2016;135(1):29-36. doi: 10.1159/000435769. Epub 2015 Aug 22.

PMID:
26303343
12.

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.

Mohty M, Azar N, Chabannon C, Le Gouill S, Karlin L, Farina L, Milkovich G, Ostermann H, Glaß B, Noppeney R, Kron F, Kron A, Hübel K.

Bone Marrow Transplant. 2018 Mar;53(3):246-254. doi: 10.1038/s41409-017-0033-0. Epub 2017 Dec 18.

PMID:
29255168
13.

Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.

Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.

Biol Blood Marrow Transplant. 2011 May;17(5):729-36. doi: 10.1016/j.bbmt.2010.08.018. Epub 2010 Oct 14.

14.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.

Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

PMID:
22760691
15.

[Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].

Ruano Camps R, Ortiz Pareja M, Vidales Mancha I, Muñoz Castillo IM, Heiniger Mazo AI.

Farm Hosp. 2013 Jul-Aug;37(4):317-21. doi: 10.7399/FH.2013.37.4.656. Spanish.

16.
17.

Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.

Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.

J Clin Apher. 2013 Oct;28(5):359-67. doi: 10.1002/jca.21280. Epub 2013 Jun 14.

PMID:
23765597
18.

Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.

Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.

Br J Haematol. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21.

PMID:
24138497
19.

Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.

Varmavuo V, Mäntymaa P, Kuittinen T, Nousiainen T, Jantunen E.

Transfusion. 2012 Aug;52(8):1785-91. doi: 10.1111/j.1537-2995.2011.03525.x. Epub 2012 Feb 5.

PMID:
22304442
20.

Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.

Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.

Transfusion. 2012 Nov;52(11):2375-81. doi: 10.1111/j.1537-2995.2012.03579.x. Epub 2012 Mar 8.

PMID:
22404694

Supplemental Content

Support Center